Compare Aurobindo Pharma with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WOCKHARDT - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WOCKHARDT AUROBINDO PHARMA/
WOCKHARDT
 
P/E (TTM) x 10.5 -18.5 - View Chart
P/BV x 2.3 1.0 233.2% View Chart
Dividend Yield % 0.5 0.0 13,922.2%  

Financials

 AUROBINDO PHARMA   WOCKHARDT
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
WOCKHARDT
Mar-18
AUROBINDO PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs8091,012 79.9%   
Low Rs504532 94.8%   
Sales per share (Unadj.) Rs281.1355.9 79.0%  
Earnings per share (Unadj.) Rs41.4-60.3 -68.6%  
Cash flow per share (Unadj.) Rs50.9-46.8 -108.8%  
Dividends per share (Unadj.) Rs2.500.01 25,000.0%  
Dividend yield (eoy) %0.40 29,388.8%  
Book value per share (Unadj.) Rs199.4257.8 77.3%  
Shares outstanding (eoy) m585.88110.63 529.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.2 107.7%   
Avg P/E ratio x15.9-12.8 -124.0%  
P/CF ratio (eoy) x12.9-16.5 -78.2%  
Price / Book Value ratio x3.33.0 110.0%  
Dividend payout %6.00 -36,439.0%   
Avg Mkt Cap Rs m384,63085,379 450.5%   
No. of employees `00017.36.3 277.1%   
Total wages/salary Rs m21,3089,371 227.4%   
Avg. sales/employee Rs Th9,500.76,295.0 150.9%   
Avg. wages/employee Rs Th1,229.41,498.3 82.1%   
Avg. net profit/employee Rs Th1,397.9-1,066.3 -131.1%   
INCOME DATA
Net Sales Rs m164,66639,369 418.3%  
Other income Rs m1,0201,202 84.8%   
Total revenues Rs m165,68640,571 408.4%   
Gross profit Rs m37,71818 206,106.6%  
Depreciation Rs m5,5801,495 373.1%   
Interest Rs m7772,555 30.4%   
Profit before tax Rs m32,380-2,830 -1,144.3%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m8,183257 3,183.9%   
Profit after tax Rs m24,229-6,669 -363.3%  
Gross profit margin %22.90 49,276.8%  
Effective tax rate %25.3-9.1 -278.2%   
Net profit margin %14.7-16.9 -86.9%  
BALANCE SHEET DATA
Current assets Rs m121,87833,796 360.6%   
Current liabilities Rs m86,80626,917 322.5%   
Net working cap to sales %21.317.5 121.9%  
Current ratio x1.41.3 111.8%  
Inventory Days Days13079 163.7%  
Debtors Days Days6889 76.6%  
Net fixed assets Rs m81,03739,664 204.3%   
Share capital Rs m586553 105.9%   
"Free" reserves Rs m116,21827,968 415.5%   
Net worth Rs m116,80428,522 409.5%   
Long term debt Rs m4,51221,731 20.8%   
Total assets Rs m211,05281,620 258.6%  
Interest coverage x42.7-0.1 -39,679.4%   
Debt to equity ratio x00.8 5.1%  
Sales to assets ratio x0.80.5 161.8%   
Return on assets %11.8-5.0 -235.1%  
Return on equity %20.7-23.4 -88.7%  
Return on capital %27.4-7.7 -356.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7279,807 823.2%   
Fx outflow Rs m34,7001,789 1,940.1%   
Net fx Rs m46,0278,019 574.0%   
CASH FLOW
From Operations Rs m19,548684 2,856.3%  
From Investments Rs m-19,5706,302 -310.5%  
From Financial Activity Rs m8,642-7,695 -112.3%  
Net Cashflow Rs m8,922-664 -1,343.7%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.3 345.7%  
FIIs % 27.7 7.7 359.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 67,757 102.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   TORRENT PHARMA  NATCO PHARMA  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 15, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS